FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977181855> ?p ?o ?g. }

• W2977181855 endingPage "287" @default.
• W2977181855 startingPage "282" @default.
• W2977181855 abstract "Objective: To investigate the optimal duration of pegylated-alpha interferon (Peg-INFα) combined with ribavirin (RBV) in treating chronic hepatitis C infection in human immunodeficiency virus (HIV)-infected patients. Methods: A multicenter prospective study was conducted. The study subjects were divided into two groups; HIV/HCV co-infections (Group A, n = 158) and control with HCV-monoinfections (Group B, n = 60). All recruited patients received standard Peg-INFα plus RBV therapy. Group A was divided into 3 subgroups according to CD4(+) cell counts: A1 subgroup, 79 cases, CD4(+) counts > 350 cells /μl, who received anti-HCV before combination antiretroviral therapy(cART); A2 subgroup, 45 cases, CD4(+) counts between 200 and 350 cells/μl, who did not start anti-HCV until they could tolerate cART well; A3 subgroup, 34 cases, CD4(+) counts < 200 cells /μl, cART was administered first, and anti-HCV therapy was started when CD4(+) counts > 200 cells/μl. The anti-HCV efficacy of two groups and 3 subgroups were compared. Statistical analysis for normal distribution and homogeneity of variance data was calculated by t-test and the counting data was analyzed by χ (2) test. The Mann-Whitney U test was used for non-normal data. A one-way analysis of variance (ANOVA) was used for the comparison of multiple groups, followed by SNK method. Multiple independent samples were used for non-parametric tests. Results: There was no significant difference in age and baseline HCV RNA levels between groups and subgroups (P > 0.05). By an intent-to-treat (ITT) analysis, in Group A, the ratio of complete early virological response (cEVR) rate was 75.3% (119/158), the ratio of end of treatment virological response (eTVR) rate was 68.4% (108/158), and the ratio of sustained virological response (SVR) rate was 48.7% (77/158); in Group B, the ratio of cEVR rate was 93.3% (56/60), the ratio of eTVR rate was 90.0% (54/60), and the ratio of SVR rate was 71.7% (43/60); The therapeutic index of Group A were lower than those of Group B (P≤0.05). By per-protocol (PP) analysis, the ratio of cEVR rate in Group A [75.2% (88/112)] was still lower than that in Group B [93.3% (56/60)], but no significant differences were found in the ratio of eTVR rate and SVR rate between 2 groups (P > 0.05). Comparing the efficacy of subgroups (A1, A2 and A3) by ITT analysis, the ratios of cEVR rate were respectively 78.5% (62/79), 75.6% (34/45) and 67.6% (23/34); the ratios of eTVR rate were respectively 68.4%(54/79), 80.0%(36/45)and 52.9%(18/34); and the ratios of SVR rate were respectively 41.8%(33/79), 64.4%(29/45)and 44.1%(15/34). The ratio of eTVR in subgroup A2 was obviously higher than that in subgroup A3 and the ratio of SVR in subgroup A2 was statistically higher than that of subgroup A1(P≤0.05). However, by PP analysis, no significant differences of the therapeutic indexes were found among the respective subgroups (P > 0.05). Conclusion: HIV-HCV co-infected patients would have better anti-HCV efficacy with Peg-INFα-2a plus RBV than HCV- monoinfected patients. The best time for initiating anti-HCV therapy in HIV-HCV co-infected patients is when CD4(+) counts 200 cells/ μl.目的： 探讨聚乙二醇干扰素α（Peg-INFα）联合利巴韦林（RBV）治疗人类免疫缺陷病毒（HIV）合并丙型肝炎病毒（HCV）感染者的最佳时机。 方法： 为前瞻性多中心研究，A组：158例，HIV合并HCV感染者；B组：对照组，60例，单一HCV感染者，均接受Peg-INFα联合RBV标准治疗。A组根据CD4(+)T淋巴细胞计数分为3个亚组：A1组，79例，CD4(+)T淋巴细胞>350个/μl，先抗HCV治疗再进行联合抗病毒治疗（cART）；A2组，45例，CD4(+)T淋巴细胞200～350个/μl，先给予cART，耐受后开始抗HCV治疗；A3组，34例，CD4(+)T淋巴细胞<200个/μl，先给予cART，待CD4(+) T淋巴细胞> 200个/μl开始抗HCV治疗。比较各组及亚组间抗HCV的疗效。对于服从正态分布、方差齐性资料两组之间采用t检验，计数资料采用χ(2)检验（或Fisher确切概率法），非正态数据采用Mann-Whitney U检验。多组均数比较采用单向方差分析，随后进行SNK检验。多组疗效比较采用多个独立样本非参数检验。 结果： 各组及亚组年龄、基线HCV RNA水平，差异无统计学意义（P值均> 0.05）。两组意向性分析：A组完全早期病毒学应答率（cEVR）率75.3%（119/158），治疗结束时病毒学应答（eTVR）率68.4%（108/158），持续病毒学应答（SVR）率48.7%（77/158）；B组cEVR率93.3%（56/60），eTVR率90.0%（54/60），SVR率71.7%（43/60），A组各疗效指标明显低于B组，差异有统计学意义（P值均< 0.05）。经过符合方案分析，A组cEVR率仍低于B组（P < 0.05），但eTVR率及SVR率与B组比较，差异无统计学意义（P值均> 0.05）。A组各亚组间疗效比较，意向性分析：A1亚组cEVR率78.5%（62/79），eTVR率68.4%（54/79），SVR率41.8%（33/79）；A2亚组cEVR率75.6%（34/45），eTVR率80.0%（36/45），SVR率64.4%（29/45）；A3亚组cEVR率67.6%（23/34），eTVR率52.9%（18/34），SVR率44.1%（15/34）。A2亚组的eTVR率、SVR率分别明显高于A3、A1亚组，差异有统计学意义（P值均< 0.05）。经过符合方案分析，各亚组疗效的差异无统计学意义（P值均> 0.05）。 结论： HIV合并HCV感染使用Peg-INFα-2a联合RBV可获得良好抗HCV疗效，患者CD4(+)T淋巴细胞计数为200个/μl时，是开始抗HCV治疗的最佳时机。." @default.
• W2977181855 created "2019-10-03" @default.
• W2977181855 creator A5003297746 @default.
• W2977181855 creator A5007202894 @default.
• W2977181855 creator A5018396033 @default.
• W2977181855 creator A5033412838 @default.
• W2977181855 creator A5038652783 @default.
• W2977181855 creator A5041341594 @default.
• W2977181855 creator A5045423164 @default.
• W2977181855 creator A5056545316 @default.
• W2977181855 creator A5056903875 @default.
• W2977181855 creator A5079282835 @default.
• W2977181855 creator A5087287145 @default.
• W2977181855 date "2018-04-20" @default.
• W2977181855 modified "2023-09-27" @default.
• W2977181855 title "[Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients]." @default.
• W2977181855 doi "https://doi.org/10.3760/cma.j.issn.1007-3418.2018.04.010" @default.
• W2977181855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29996340" @default.
• W2977181855 hasPublicationYear "2018" @default.
• W2977181855 type Work @default.
• W2977181855 sameAs 2977181855 @default.
• W2977181855 citedByCount "0" @default.
• W2977181855 crossrefType "journal-article" @default.
• W2977181855 hasAuthorship W2977181855A5003297746 @default.
• W2977181855 hasAuthorship W2977181855A5007202894 @default.
• W2977181855 hasAuthorship W2977181855A5018396033 @default.
• W2977181855 hasAuthorship W2977181855A5033412838 @default.
• W2977181855 hasAuthorship W2977181855A5038652783 @default.
• W2977181855 hasAuthorship W2977181855A5041341594 @default.
• W2977181855 hasAuthorship W2977181855A5045423164 @default.
• W2977181855 hasAuthorship W2977181855A5056545316 @default.
• W2977181855 hasAuthorship W2977181855A5056903875 @default.
• W2977181855 hasAuthorship W2977181855A5079282835 @default.
• W2977181855 hasAuthorship W2977181855A5087287145 @default.
• W2977181855 hasConcept C126322002 @default.
• W2977181855 hasConcept C127413603 @default.
• W2977181855 hasConcept C142462285 @default.
• W2977181855 hasConcept C203014093 @default.
• W2977181855 hasConcept C2522874641 @default.
• W2977181855 hasConcept C2776178377 @default.
• W2977181855 hasConcept C2776408679 @default.
• W2977181855 hasConcept C2776455275 @default.
• W2977181855 hasConcept C2776461080 @default.
• W2977181855 hasConcept C2777275308 @default.
• W2977181855 hasConcept C2780040827 @default.
• W2977181855 hasConcept C2909179924 @default.
• W2977181855 hasConcept C3013748606 @default.
• W2977181855 hasConcept C71924100 @default.
• W2977181855 hasConcept C78519656 @default.
• W2977181855 hasConcept C90924648 @default.
• W2977181855 hasConcept C99476002 @default.
• W2977181855 hasConceptScore W2977181855C126322002 @default.
• W2977181855 hasConceptScore W2977181855C127413603 @default.
• W2977181855 hasConceptScore W2977181855C142462285 @default.
• W2977181855 hasConceptScore W2977181855C203014093 @default.
• W2977181855 hasConceptScore W2977181855C2522874641 @default.
• W2977181855 hasConceptScore W2977181855C2776178377 @default.
• W2977181855 hasConceptScore W2977181855C2776408679 @default.
• W2977181855 hasConceptScore W2977181855C2776455275 @default.
• W2977181855 hasConceptScore W2977181855C2776461080 @default.
• W2977181855 hasConceptScore W2977181855C2777275308 @default.
• W2977181855 hasConceptScore W2977181855C2780040827 @default.
• W2977181855 hasConceptScore W2977181855C2909179924 @default.
• W2977181855 hasConceptScore W2977181855C3013748606 @default.
• W2977181855 hasConceptScore W2977181855C71924100 @default.
• W2977181855 hasConceptScore W2977181855C78519656 @default.
• W2977181855 hasConceptScore W2977181855C90924648 @default.
• W2977181855 hasConceptScore W2977181855C99476002 @default.
• W2977181855 hasIssue "4" @default.
• W2977181855 hasLocation W29771818551 @default.
• W2977181855 hasOpenAccess W2977181855 @default.
• W2977181855 hasPrimaryLocation W29771818551 @default.
• W2977181855 hasRelatedWork W118298973 @default.
• W2977181855 hasRelatedWork W2007062588 @default.
• W2977181855 hasRelatedWork W2040614867 @default.
• W2977181855 hasRelatedWork W2044547797 @default.
• W2977181855 hasRelatedWork W2063503814 @default.
• W2977181855 hasRelatedWork W2082200384 @default.
• W2977181855 hasRelatedWork W2109119062 @default.
• W2977181855 hasRelatedWork W2358339988 @default.
• W2977181855 hasRelatedWork W2410487329 @default.
• W2977181855 hasRelatedWork W2416699442 @default.
• W2977181855 hasVolume "26" @default.
• W2977181855 isParatext "false" @default.
• W2977181855 isRetracted "false" @default.
• W2977181855 magId "2977181855" @default.
• W2977181855 workType "article" @default.